Publications
2024
Kawashima, M, et al. The safety and tolerability of berdazimer gel, 10.3% in Japanese patients with molluscum contagiosum. JAAD Int. Oct 4, 2024. https://www.jaadinternational.org/article/S2666-3287(24)00153-6/fulltext
Cartwright M, Maeda-Chubachi T, Enloe C, Stripling S. A retrospective claims analysis of US pediatricians prescribing practices for the treatment of Molluscum Contagiosum. Open J Pediatr Child Health. 2024; 9(1): 045-049.
Cartwright M, Maeda-Chubachi T, Enloe C, Stripling S, Hebert A. How are pediatricians treating molluscum contagiosum? results from in-depth interviews. Open J Pediatr Child Health. 2024; 9(1): 040-044.
Paller AS, Green LJ, Silverberg N, et al. Berdazimer gel for molluscum contagiosum in patients with atopic dermatitis. Pediatr Dermatol. Published online February 27, 2024. doi:10.1111/pde.15575
2023
Sugarman JL, Hebert A, Browning JC, Paller AS, Stripling S, Green LJ, Cartwright M, Enloe C, Wells N, Maeda-Chubachi T. Berdazimer gel for molluscum contagiosum: An integrated analysis of 3 randomized controlled trials. J Am Acad Dermatol. 2023 Oct 5:S0190-9622(23)02890-6. doi: 10.1016/j.jaad.2023.09.066.Epub ahead of print.
Ward BM, Riccio DA, Cartwright M, Maeda-Chubachi T. The Antiviral Effect of Berdazimer Sodium on Molluscum Contagiosum Virus Using a Novel In Vitro Methodology. Viruses. 2023 Nov 30;15(12):2360. d
Browning JC, Cartwright M, Thorla I Jr, Martin SA, Olayinka-Amao O, Maeda- Chubachi T. A Patient-Centered Perspective of Molluscum Contagiosum as Reported by B-SIMPLE4 Clinical Trial Patients and Caregivers: Global Impression of Change and Exit Interview . Am J Clin Dermatol. 2023 Jan;24(1):119-133.
2022
A Patient‑Centered Perspective of Molluscum Contagiosum as Reported by B‑SIMPLE4 Clinical Trial Patients and Caregivers: Global Impression of Change and Exit Interview Substudy Results
Patient and Caregiver Experiences with Molluscum Contagiosum: Results from an Exit Interview Conducted with Phase 3 Study Participants
Efficacy and Safety of Topical Nitric Oxide−Releasing Berdazimer Gel in Patients With Molluscum Contagiosum: Results from B-SIMPLE4, A Phase 3 Randomized Clinical Trial
Efficacy and Safety of Topical Nitric Oxide−Releasing Berdazimer Gel in Patients With Molluscum Contagiosum
Berdazimer 10.3% Gel, a Nitric Oxide-Releasing Topical Medication for Molluscum Contagiosum, Triggers BOTE (Beginning Of The End) Inflammation and Accelerates Resolution
Clinical Development Program of Novel Topical Nitric Oxide Releasing Medication Berdazimer Gel 10.3% for the
Once-Daily Treatment of Molluscum Contagiosum
2021
SB206, a Nitric Oxide–releasing Topical Medication Induces the BOTE (Beginning-of-the-End) Sign and Molluscum Clearance
2020
A Nitric Oxide-releasing Topical Medication as a Potential Treatment Option for Atopic Dermatitis Through Antimicrobial and Anti-inflammatory Activity
2019
Efficacy and Tolerability of an Investigational Nitric Oxide-releasing Topical Gel in Patients With Molluscum Contagiosum: A Randomized Clinical Trial
NVN1000, a Novel Nitric Oxide-Releasing Compound, Inhibits HPV-18 Virus Production by Interfering with E6 and E7 Oncoprotein Functions
2018
A Phase 2, Controlled, Dose-Ranging Study of SB208, an Investigational Topical Nitric Oxide-Releasing Drug, for the Treatment of Tinea Pedis
Nitric Oxide-Releasing Macromolecule Exhibits Broad-Spectrum Antifungal Activity and Utility as a Topical Treatment for Superficial Fungal Infections
A Phase 2 Controlled Study of SB206, a Topical Nitric Oxide-Releasing Drug for Extragenital Wart Treatment